<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn></journal-meta><article-meta><article-id pub-id-type="pmid">7914427</article-id><article-id pub-id-type="pmc">2033513</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Docetaxel (Taxotere), a novel taxoid, in the treatment of advanced colorectal carcinoma: an EORTC Early Clinical Trials Group Study.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sternberg</surname><given-names>C. N.</given-names></name></contrib><contrib contrib-type="author"><name><surname>ten Bokkel Huinink</surname><given-names>W. W.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Smyth</surname><given-names>J. F.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Bruntsch</surname><given-names>V.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Dirix</surname><given-names>L. Y.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Pavlidis</surname><given-names>N. A.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Franklin</surname><given-names>H.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Wanders</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Le Bail</surname><given-names>N.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kaye</surname><given-names>S. B.</given-names></name></contrib></contrib-group><aff>Regina Elena Cancer Institute, Rome, Italy.</aff><pub-date pub-type="ppub"><month>8</month><year>1994</year></pub-date><volume>70</volume><issue>2</issue><fpage>376</fpage><lpage>379</lpage><abstract><p>Docetaxel (Taxotere), a new semisynthetic taxoid, is a potentially important chemotherapeutic agent for the treatment of cancer. Forty patients with bidimensionally measurable advanced adenocarcinoma of the colon were treated with docetaxel 100 mg m-2 every 3 weeks as a 1 h infusion without routine premedication. Thirty-nine patients were eligible: 23 males and 16 females. Median age was 60 years (range 41-75) and WHO performance status 1 (0-2). Prior adjuvant chemotherapy was performed in four patients and prior radiotherapy in nine patients. Bidimensionally measurable disease sites included: liver in 26 patients, lymph nodes and abdominal/peritoneal masses in 13, lung/mediastinal masses in ten and subcutaneous nodes in four. The median number of cycles given was 2 (range 1-15). Thirty-three patients were evaluable for response. One patient (3%) achieved a complete response and two (6%) (95% confidence limits 0-14%) a partial response. Side-effects were similar to those observed in other studies. Docetaxel, given at this dosage and schedule, has minimal activity in the treatment of colorectal carcinoma.</p></abstract></article-meta></front><body><supplementary-material content-type="scanned-pages"><graphic xlink:href="brjcancer00054-0196.tif" xlink:title="scanned-page" xlink:role="376" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00054-0197.tif" xlink:title="scanned-page" xlink:role="377" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00054-0198.tif" xlink:title="scanned-page" xlink:role="378" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00054-0199.tif" xlink:title="scanned-page" xlink:role="379" mimetype="image" mime-subtype="tiff"/></supplementary-material></body></article>

